Linda Metheny-Barlow to Survival Rate
This is a "connection" page, showing publications Linda Metheny-Barlow has written about Survival Rate.
Connection Strength
0.090
-
Dohm A, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, Ruiz J. Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. Int J Biol Markers. 2019 Mar; 34(1):90-97.
Score: 0.034
-
Cramer CK, Alphonse-Sullivan N, Isom S, Metheny-Barlow LJ, Cummings TL, Page BR, Brown DR, Blackstock AW, Peiffer AM, Strowd RE, Rapp S, Lesser GJ, Shaw EG, Chan MD. Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial. J Cancer Res Clin Oncol. 2019 Feb; 145(2):337-344.
Score: 0.034
-
Vern-Gross TZ, Lawrence JA, Case LD, McMullen KP, Bourland JD, Metheny-Barlow LJ, Ellis TL, Tatter SB, Shaw EG, Urbanic JJ, Chan MD. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. J Neurooncol. 2012 Dec; 110(3):381-8.
Score: 0.022